Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure

Bone Marrow Transplantation

Volumn 32, Issue 9, 2003, Pages 869-872

  Subira M ^a   Sureda, A ^a   Ancin I ^a   Martino, R ^a   Altes A ^a   Brunet, S ^a   Sierra, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Allogeneic stem cell transplantation; Conditioning related toxicities; Outpatient transplantation

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; NORFLOXACIN;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLADDER DISEASE; BLOOD TOXICITY; CARDIOTOXICITY; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LENGTH OF STAY; LUNG TOXICITY; MALE; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SIBLING; TREATMENT PLANNING;

ADULT; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEASIBILITY STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; NEUTROPENIA; RISK FACTORS; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 0242468186     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704254     Document Type: Article

References (10)

1. Barret J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111: 6-17.
2. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 2000; 85: 304-313.
3. Champlin R, Khouri L, Komblau S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11: 87-95.
4. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumour effects. Blood 2001; 97: 3390-4000.
5. Weissinger F, Sandmaier BM, Maloney DG et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98: 3584-3588.
6. Miler AB, Hoogstraten B, Syaquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
7. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 12-20.
8. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using a fludarabine-based nonablative chemotherapy and allogeneic blood progenitor transplantation as treatment for lymphoid malignancy. J Clin Oncol 1998; 8: 2817-2824.
9. Schetelig J, Kröger N, Held TK et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002; 87: 299-305.
10. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cyto-reduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.